search button
Open Access

Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials

  • Authors:
    • Changcheng Guo
    • Wenyu Gu
    • Min Liu
    • Bo Peng
    • Xudong Yao
    • Bin Yang
    • Junhua Zheng

  • View Affiliations

  • Published online on: December 23, 2015     https://doi.org/10.3892/etm.2015.2957
  • Pages: 853-863

  • Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of the present meta-analysis was to evaluate the efficacy and safety of testosterone replacement therapy in men with hypogonadism. A search was conducted for appropriate randomized controlled trials and the data from 16 trials were pooled. The intended primary outcome of the present study was to determine the efficacy and safety of testosterone replacement therapy. The current data demonstrated that scores for Aging Male Symptoms (AMS) were significantly reduced following testosterone replacement therapy, with a mean decrease in AMS score of 1.52 [95% confidence interval (CI), 0.72 to 2.32; P=0.0002]. Testosterone replacement therapy increased lean body mass [mean difference (MD), 1.22; 95% CI, 0.33 to 2.11; P=0.007], reduced fat mass in a non‑significantly manner (MD, ‑0.85; 95% CI, ‑1.74 to 0.04; P=0.06) and significantly reduced total cholesterol (MD, ‑0.16; 95% CI, ‑0.29 to ‑0.03; P=0.01). No significant differences were identified in body weight (MD, 0.09; 95% CI, ‑1.13 to 1.31; P=0.89), body mass index (MD, 0.10; 95% CI, ‑0.62 to 0.82; P=0.78) or bone mineral density (MD, ‑0.01; 95% CI, ‑0.03 to 0.02; P=0.60). Average prostate volume increased (MD, 1.58; 95% CI, 0.6 to 2.56; P=0.002) following testosterone replacement therapy, but the levels of prostate‑specific antigen (PSA) (MD, 0.10; 95% CI, ‑0.03 to 0.22; P=0.14) and the International Prostate Symptom Scores (MD, 0.01; 95% CI, ‑0.37 to 0.39; P=0.96) did not change. In conclusion, testosterone replacement therapy improves quality of life, increases lean body mass, significantly decreases total cholesterol, and is well‑tolerated and safe for men with hypogonadism who are exhibiting PSA levels of <4 ng/ml.
View Figures
View References

Related Articles

Journal Cover

March-2016
Volume 11 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Guo C, Gu W, Liu M, Peng B, Yao X, Yang B and Zheng J: Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials. Exp Ther Med 11: 853-863, 2016.
APA
Guo, C., Gu, W., Liu, M., Peng, B., Yao, X., Yang, B., & Zheng, J. (2016). Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials. Experimental and Therapeutic Medicine, 11, 853-863. https://doi.org/10.3892/etm.2015.2957
MLA
Guo, C., Gu, W., Liu, M., Peng, B., Yao, X., Yang, B., Zheng, J."Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials". Experimental and Therapeutic Medicine 11.3 (2016): 853-863.
Chicago
Guo, C., Gu, W., Liu, M., Peng, B., Yao, X., Yang, B., Zheng, J."Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials". Experimental and Therapeutic Medicine 11, no. 3 (2016): 853-863. https://doi.org/10.3892/etm.2015.2957